Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Active:	No
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT04105010
Trial Phases:	Phase II	Protocol IDs:	DZ2019J0005 (primary) NCI-2021-03769
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Dizal Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT04105010

Summary

This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate
the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients
with peripheral T cell lymphoma (PTCL), who have relapsed from or are
refractory/intolerant to standard systemic treatment.

Phase 1 part:

Around 20~40 patients will be subsequently enrolled into 2 different dose ascending
cohorts. Additional 10~20 patients may be enrolled to further explore a selected dose
defined by dose escalation cohorts.

Phase 2 part:

After the recommended phase 2 dose (RP2D) is defined, a phase 2 single-arm open-label
pivotal study will be conducted to assess anti-tumor efficacy and safety of AZD4205 at
RP2D in patients with refractory or relapsed PTCL.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.